Pfizer raises revenue guidance as non-Covid products drive quarterly beat

Pfizer beat quarterly analyst estimates and raised the low end of its full-year revenue guidance, driven by the strength of non-Covid products. The company simultaneously cut its full-year revenue forecast for Covid products to $4 billion, down from approximately $5 billion previously.